Table 1.
The German ClinSurv HIV cohort in the study period 2006–2013
| Year/quarter | Patients under observation | Patients under ART time | Observation time | Time under ART or interruption | ART status unknown | Art naive | ART regimens with approved drugs exclusively | ART regimens containing non-approved drugs | Treatment interruptions | ART experienced | TCMs in the CSH | Proportion of interruptions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Days | |||||||||||
| 2006/I | 8717 | 6986 | 753553 | 613673 | 8211 | 131728 | 516827 | 29909 | 66937 | 81.4% | 84.5% | 10.9% |
| 2006/II | 8856 | 7104 | 773115 | 630625 | 7907 | 134629 | 533732 | 32431 | 64462 | 81.6% | 85.3% | 10.2% |
| 2006/III | 9002 | 7214 | 792169 | 646716 | 7742 | 137766 | 547485 | 36102 | 63129 | 81.6% | 86.2% | 9.8% |
| 2006/IV | 9075 | 7281 | 803312 | 655415 | 7530 | 140415 | 558719 | 36453 | 60243 | 81.6% | 87.0% | 9.2% |
| 2007/I | 9267 | 7434 | 798257 | 652832 | 7219 | 138281 | 560733 | 33462 | 58637 | 81.8% | 87.7% | 9.0% |
| 2007/II | 9407 | 7552 | 820040 | 671081 | 7345 | 141682 | 579930 | 33382 | 57769 | 81.8% | 88.4% | 8.6% |
| 2007/III | 9564 | 7689 | 844690 | 690514 | 7304 | 146945 | 595635 | 38313 | 56566 | 81.7% | 89.1% | 8.2% |
| 2007/IV | 9683 | 7828 | 855138 | 704369 | 6948 | 143877 | 609239 | 39403 | 55727 | 82.4% | 89.5% | 7.9% |
| 2008/I | 9758 | 7937 | 853480 | 705518 | 6344 | 141676 | 619880 | 31297 | 54341 | 82.7% | 89.8% | 7.7% |
| 2008/II | 9903 | 8069 | 863850 | 716324 | 5985 | 141595 | 632750 | 31325 | 52249 | 82.9% | 90.4% | 7.3% |
| 2008/III | 10031 | 8206 | 884551 | 737289 | 5895 | 141423 | 656479 | 28383 | 52427 | 83.4% | 90.7% | 7.1% |
| 2008/IV | 10124 | 8340 | 896771 | 752357 | 5982 | 138495 | 678973 | 22195 | 51189 | 83.9% | 91.0% | 6.8% |
| 2009/I | 10222 | 8484 | 886182 | 747140 | 5303 | 133792 | 677700 | 21820 | 47620 | 84.3% | 91.3% | 6.4% |
| 2009/II | 10384 | 8624 | 910943 | 769502 | 4859 | 136659 | 700526 | 21972 | 47004 | 84.5% | 91.6% | 6.1% |
| 2009/III | 10569 | 8814 | 934456 | 791390 | 4779 | 138362 | 722970 | 22322 | 46098 | 84.7% | 91.8% | 5.8% |
| 2009/IV | 10697 | 8989 | 946177 | 808947 | 4660 | 132635 | 742278 | 22853 | 43816 | 85.5% | 92.0% | 5.4% |
| 2010/I | 10799 | 9140 | 936276 | 805104 | 4473 | 126765 | 741693 | 22313 | 41098 | 86.0% | 92.3% | 5.1% |
| 2010/II | 10956 | 9290 | 958828 | 827947 | 4376 | 126573 | 768583 | 21791 | 37573 | 86.3% | 92.4% | 4.5% |
| 2010/III | 11123 | 9468 | 980925 | 849665 | 4289 | 127041 | 792663 | 21195 | 35807 | 86.6% | 92.4% | 4.2% |
| 2010/IV | 11171 | 9617 | 989771 | 865271 | 3898 | 120674 | 808229 | 22985 | 34057 | 87.4% | 92.3% | 3.9% |
| 2011/I | 11258 | 9761 | 974608 | 859468 | 3418 | 111790 | 803378 | 24123 | 31967 | 88.2% | 92.3% | 3.7% |
| 2011/II | 11333 | 9870 | 994656 | 880602 | 3347 | 110776 | 824465 | 25470 | 30667 | 88.5% | 92.3% | 3.5% |
| 2011/III | 11467 | 10030 | 1013429 | 901100 | 3305 | 109118 | 845603 | 26049 | 29448 | 88.9% | 92.4% | 3.3% |
| 2011/IV | 11480 | 10089 | 1021398 | 910156 | 3063 | 108245 | 857736 | 24301 | 28119 | 89.1% | 92.5% | 3.1% |
| 2012/I | 11588 | 10196 | 1014121 | 906295 | 3068 | 104831 | 858296 | 21730 | 26269 | 89.4% | 92.6% | 2.9% |
| 2012/II | 11612 | 10261 | 1019125 | 914177 | 2916 | 102114 | 867192 | 20862 | 26123 | 89.7% | 92.6% | 2.9% |
| 2012/III | 11651 | 10338 | 1032814 | 929619 | 2661 | 100626 | 883234 | 21460 | 24925 | 90.0% | 92.4% | 2.7% |
| 2012/IV | 11574 | 10334 | 1023954 | 925347 | 2423 | 96245 | 882817 | 20421 | 22109 | 90.4% | 92.5% | 2.4% |
| 2013/I | 11428 | 10229 | 980141 | 890397 | 2109 | 87707 | 852262 | 18571 | 19564 | 90.8% | 92.7% | 2.2% |
| 2013/II | 11092 | 9978 | 960764 | 876969 | 1508 | 82345 | 843148 | 16594 | 17227 | 91.3% | 92.8% | 2.0% |
| 2103/III | 10760 | 9725 | 879002 | 804520 | 1199 | 73313 | 775500 | 14296 | 14724 | 91.5% | 92.7% | 1.8% |
| 2013/IV | 8358 | 7610 | 363973 | 331301 | 621 | 31848 | 317585 | 7227 | 6489 | 91.0% | 92.5% | 2.0% |
Determined patient numbers, observation time and proportions of treated patients as well as TCM use and treatment interruptions in the ClinSurv HIV cohort.